Evolving epidemiology of hepatitis C virus, Clinical Microbiology and Infection, vol.17, issue.2, pp.107-115, 2011. ,
DOI : 10.1111/j.1469-0691.2010.03432.x
Global epidemiology of hepatitis C virus infection, The Lancet Infectious Diseases, vol.5, issue.9, pp.558-567, 2005. ,
DOI : 10.1016/S1473-3099(05)70216-4
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.360, issue.18, pp.1827-1838, 2009. ,
DOI : 10.1056/NEJMoa0806104
Boceprevir for Untreated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1195-1206, 2011. ,
DOI : 10.1056/NEJMoa1010494
URL : https://hal.archives-ouvertes.fr/hal-00867494
Chronic hepatitis C virus infection: developing direct-acting antiviral agents for treatment. Rockville, MD: Food and Drug Administration, 2010. ,
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration, Hepatology, vol.376, issue.6, pp.1801-1808, 2011. ,
DOI : 10.1002/hep.24272
Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus???Infected Patients Following TMC435 Monotherapy, Gastroenterology, vol.143, issue.5, pp.1176-1178, 2012. ,
DOI : 10.1053/j.gastro.2012.07.117
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life, Proceedings of the National Academy of Sciences, vol.110, issue.10, pp.1103991-3996 ,
DOI : 10.1073/pnas.1203110110
Estimation of dynamical model parameters taking into account undetectable marker values, BMC Medical Research Methodology, vol.49, issue.1, p.38, 2006. ,
DOI : 10.1111/1467-9876.00207
Design evaluation and optimization for models of hepatitis C viral dynamics, Statistics in Medicine, vol.38, issue.18, pp.1045-1056, 2011. ,
DOI : 10.1002/sim.4191
URL : https://hal.archives-ouvertes.fr/inserm-00615142
Estimation of HIV dynamic parameters, pp.2463-2485, 1998. ,
Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.5, pp.465-479, 2001. ,
DOI : 10.1023/A:1012247131190
Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model, Pharmaceutical Research, vol.19, issue.12, pp.1835-1840, 2002. ,
DOI : 10.1023/A:1021441407898
Some Alternatives to Asymptotic Tests for the Analysis of Pharmacogenetic Data Using Nonlinear Mixed Effects Models, Biometrics, vol.21, issue.1, pp.146-155, 2012. ,
DOI : 10.1111/j.1541-0420.2011.01665.x
URL : https://hal.archives-ouvertes.fr/inserm-00709820
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy, Science, vol.282, issue.5386, pp.103-107, 1998. ,
DOI : 10.1126/science.282.5386.103
Understanding silibinin???s modes of action against HCV using viral kinetic modeling, Journal of Hepatology, vol.56, issue.5, pp.1019-1024, 2012. ,
DOI : 10.1016/j.jhep.2011.12.012
A hepatitis C viral kinetic model that allows for time-varying drug effectiveness, Antivir Ther, vol.13, pp.919-926, 2008. ,
Abbott RealTime Hepatitis C Virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV Assays for Prediction of Sustained Virological Response to Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients, Journal of Clinical Microbiology, vol.47, issue.2, pp.385-389, 2009. ,
DOI : 10.1128/JCM.01753-08
Maximum likelihood estimation in nonlinear mixed effects models, Computational Statistics & Data Analysis, vol.49, issue.4, pp.1020-1038, 2005. ,
DOI : 10.1016/j.csda.2004.07.002
Ways to fit a PK model with some data below the quantification limit, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.5, pp.481-504, 2001. ,
DOI : 10.1023/A:1012299115260
Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model, Computational Statistics & Data Analysis, vol.51, issue.3, pp.1562-1574, 2006. ,
DOI : 10.1016/j.csda.2006.05.007
URL : https://hal.archives-ouvertes.fr/inserm-00182360
Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm, Statistics in Medicine, vol.50, pp.2582-2600, 2011. ,
DOI : 10.1002/sim.4286
URL : https://hal.archives-ouvertes.fr/inserm-00643832
Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm, Journal of Pharmacokinetics and Pharmacodynamics, vol.30, issue.4, pp.317-339, 2009. ,
DOI : 10.1007/s10928-009-9124-x
URL : https://hal.archives-ouvertes.fr/inserm-00406739
Design in nonlinear mixed effects models: Optimization using the Fedorov???Wynn algorithm and power of the Wald test for binary covariates, Statistics in Medicine, vol.39, issue.28, pp.5162-5179, 2007. ,
DOI : 10.1002/sim.2910
URL : https://hal.archives-ouvertes.fr/hal-00263513
Optimization of Individual and Population Designs Using Splus, Journal of Pharmacokinetics and Pharmacodynamics, vol.30, issue.6, pp.417-443, 2003. ,
DOI : 10.1023/B:JOPA.0000013000.59346.9a
A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure, Clinical Pharmacology & Therapeutics, vol.308, issue.6, pp.706-713, 2010. ,
DOI : 10.1016/j.csda.2004.07.002
URL : https://hal.archives-ouvertes.fr/hal-00637434
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus, Science Translational Medicine, vol.2, issue.30, pp.30-32, 2010. ,
DOI : 10.1126/scitranslmed.3000544
Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?, Antiviral Therapy, vol.17, issue.6 Pt B, pp.1171-1182, 2012. ,
DOI : 10.3851/IMP2428
Rapid decrease of wild-type hepatitis C virus on telaprevir treatment, Antivir Ther, vol.14, pp.591-595, 2009. ,